TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05995015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal CD19-specific CAR gene-engineered T cells
Description: Infusion of 4SCAR19U cells
Study: NCT05039333

Intervention type: DEVICE
Intervention: RUS(TM) software : surgical navigation
Description: This clinical trial is a sponsor-led clinical trial, and it is intended to confirm that RUS™, a surgical navigation system certified for level 2 endoscopic imaging treatment planning software, can be applied to real people as a clinical study by using preoperative CT and to confirm the safety of surgery. In addition, the secondary research objective was to examine the accuracy of the intra-abdominal surgical navigation system provided by RUS™ including: 1) the accuracy of the undulation prediction model, 2) the accuracy of the trocar insertion position, 3) the adequacy of 3D reconstruction of the main vessels, 4) the accuracy of the major vessel branching distances, 5) the intraoperative bleeding volume and operating time, and 6) the postoperative hospitalization period and complication rate were compared with the past control group.
Study: NCT04700384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Operative Assistant Training
Description: Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote-Based Expert Instructor Training
Description: Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
Study: NCT05744336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 Immersive Virtual Reality (VR)
Description: Participants in Group 1 Immersive Virtual Reality (VR) participants wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 2 Control Group
Description: Group 2 control group participants have no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
Study: NCT06181461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong's Mobilization
Description: Group A received Gong's mobilization with routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaltenborn Mobilization
Description: Group B will receive Kaltenborn mobilization (Grade III posterior translation) with routine therapy. Posterior translation is applied in 30-sec sets, repeated 15 times over 10 mins, with 10-sec rests. Routine physical therapy includes 30-45 min sessions with 15-min TENS. Patients follow daily care instructions, use the affected shoulder in daily activities, and perform pendulum and active shoulder exercises twice a day.
Study: NCT05275881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Practices
Description: In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
Study: NCT05861739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endometriosis Self-care Support Program
Description: ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
Study: NCT06278207

Intervention type: DRUG
Intervention: Finerenone (BAY 94-8862)
Description: 10 mg or 20 mg daily
Study: NCT05939440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Cost of Care (P-COC) intervention
Description: As in Arm description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As in Arm description
Study: NCT05257941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IT Injection
Description: an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back
Study: NCT04977869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
Study: NCT06137833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: APPOPRTAL®
Description: 1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
Study: NCT05315947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.
Study: NCT06292000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AM Exercise
Description: Morning (0-3 hours from habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AM Exercise
Description: Morning (0-3 hours from habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM Exercise
Description: Evening (9-12 hours after habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM Exercise
Description: Evening (9-12 hours after habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
Study: NCT05715528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir
Description: Tablet administered orally without regard to food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeldesivir Placebo
Description: Tablet administered orally without regard to food.
Study: NCT05034939

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLEX Vessel Prep System
Description: The FLEX Vessel Prep System™ is an over-the-wire sheathed catheter with a three-strut treatment element near the distal tip. As the device is pulled back in a retrograde fashion through the target lesion, the Treatment Element flexes providing continuous engagement along the lesion to create controlled depth micro-incisions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty
Description: The brand and type of PTA balloon(s) used will be at the discretion of the treating physician and used according to its Instructions for Use (IFU). PTA balloons consist of an over-the-wire catheter with a balloon fixed at the distal tip. Within the lesion the balloon is inflated to a pressure that allows full effacement.
Study: NCT05351151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ultra-sound guided maxillary and mandibular nerve blocks
Description: Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of Lidocaine 1%
Description: Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy
Study: NCT06170905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein-preload OGTT
Description: Intake of 25 g whey protein diluted in water 30 minutes prior to the start of a regular 75 g oral glucose tolerance test
Study: NCT03999658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-3031
Description: anti-PD-L1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-3031
Description: anti-PD-L1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-3031
Description: anti-PD-L1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-3031
Description: anti-PD-L1 antibody
Study: NCT05482074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Oral, twice a day, dosage per protocol, per 28 day cycle
Study: NCT04262635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab, Capecitabine
Description: Maintenance treatment ( ArmA )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Maintenance treatment ( ArmB )
Study: NCT04914325

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: peek
Description: After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: peek
Description: After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
Study: NCT05769023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention test
Description: behavioral sessions to promote vaccines
Study: NCT06601660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Physical Training
Description: A group of women who will perform the combined physical training (CPT) at morning from 7 am to 10 am, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night Physical Training
Description: A group of women who will perform the combined physical training (CPT) at morning from 6 pm to 9 pm, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Group of women who will not receive intervention with combined physical training, but will be evaluated before and after 8 weeks, and monitored, without any intervention with physical exercise.
Study: NCT05371509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy (MT) nozzle
Description: Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nozzle
Description: The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
Study: NCT06397716

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALDH2 Genotyping
Description: Cheek swab for PCR testing of ALDH2 genotype.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: ALDH2 Genotyping
Description: Cheek swab for PCR testing of ALDH2 genotype.
Study: NCT06716333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group (12-Week Wrestling Training)
Description: The intervention consists of a structured 12-week intensive wrestling training program designed specifically for male wrestlers aged 12-14 years. This program was conducted at athlete training centers equipped with international standard facilities, and led by professional coaches. The training included 5 sessions per week, each lasting approximately 80 minutes, with a total weekly duration of 400 minutes. Each session consisted of 20 minutes of gymnastic warm-up, 50 minutes of basic technical and strength exercises (e.g., squats, push-ups, deadlifts), and 10 minutes of stretching.
Study: NCT05609591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid diet group
Description: Fluid diet including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were given to children for bowel preparation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition group
Description: 100% short peptide enteral nutrition are given to children for bowel preparation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low residual diet group
Description: Low residua diet included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. were given to children for bowel preparation
Study: NCT03594630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Receive active surveillance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of Rectum
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of Rectum
Description: Undergo surgical resection
Study: NCT05005234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH925
Description: Administered as an oral tablet formulation
Study: NCT06725225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom cluster-based care intervention
Description: The patient symptoms were surveyed to develop a symptom cluster care intervention plan. The specific steps were as follows: a research team was established, relevant literature was reviewed, and qualitative interviews were conducted. Guided by symptom management theory and the Knowledge-Attitude-Practice (KAP) behavior model, a draft of the care intervention was created. This draft was then refined through expert consultation to finalize the intervention plan.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care intervention
Description: Standard nursing intervention. This refers to routine clinical care without a specific care plan tailored to the patient's symptoms. For example, if a patient has symptoms, the nurse assists the patient in notifying the doctor but does not provide any special treatment themselves
Study: NCT06727240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The interventional device is a coupling device intended to prevent mechanical complications during peripheral intravenous infusions. While control will not receive the device.
Study: NCT06730321

Intervention type: OTHER
Intervention: Observations on clinicopathological factors influencing the assessment score of surgery
Description: Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
Study: NCT06735547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients in the Telerehabilitation group will perform an average of three therapy sessions per week, with data collected and monitored by TRAK's physiotherapists. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: Patients in the conventional group will be assessed by a professional physiotherapist, scheduling appointments according to their own preferences and disponibility. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
Study: NCT06735352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality intervention
Description: Evaluated the effect of virtual reality use in elderly people with mild cognitive impairment compared to a control group.
Study: NCT06734221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated Peripheral Angioplasty Balloon Catheter
Description: Paclitaxel coated peripheral angioplasty balloon catheters are catheters of over the wire (OTW) type. Distal part of the catheter consists of two channels. External channel is used for inflating the balloon, and internal channel is the guide wire. Catheter has two markers enabling precise determination of balloon position in the vessel. The balloon is covered with a coating POLIGRADE® and drug paclitaxel an amount to 2.5 µg/mm2 , which is eluting during balloon inflation. Paclitaxel belongs to alkaloids group from taxanes group. It is cytostatic and it inhibits the cell cycle in G2/M phase. By inhibiting division of cells and their migration, paclitaxel allows for limiting restenosis phenomenon. Paclitaxel selectively inhibits smooth myocytes proliferation, while the endothelium cells show higher resistance to its action. In addition, paclitaxel restricts inflammatory conditions in walls of the arteries after balloon angioplasty.